董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Claire Pomeroy | 女 | Independent Director | 71 | 30.00万美元 | 1.69 | 2026-07-24 |
| Christopher Simon | 男 | Director,Chief Executive Officer and President | 62 | 1204.47万美元 | 58.75 | 2026-07-24 |
| Diane M. Bryant | 女 | Independent Director | 64 | 29.00万美元 | 0.71 | 2026-07-24 |
| Lloyd E. Johnson | 男 | Independent Director | 72 | 30.67万美元 | 1.29 | 2026-07-24 |
| Robert Abernathy | 男 | Independent Director | 71 | 30.50万美元 | 2.50 | 2026-07-24 |
| Diane M. Bryant | 女 | Independent Director | 64 | 未披露 | 未持股 | 2026-07-24 |
| Ellen M. Zane | 女 | Chair of the Board and Independent Director | 74 | 45.00万美元 | 1.94 | 2026-07-24 |
| Mark W. Kroll | 男 | Independent Director | 73 | 29.00万美元 | 2.34 | 2026-07-24 |
| Michael J. Coyle | 男 | Independent Director | 64 | 29.30万美元 | 1.54 | 2026-07-24 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| James C. D'Arecca | 男 | Executive Vice President, Chief Financial Officer | 55 | 362.30万美元 | 5.98 | 2026-07-24 |
| Christopher Simon | 男 | Director,Chief Executive Officer and President | 62 | 1204.47万美元 | 58.75 | 2026-07-24 |
| Michelle Basil | 女 | Executive Vice President and General Counsel | 54 | 340.95万美元 | 8.65 | 2026-07-24 |
| Roy Galvin | 男 | Executive Vice President, Chief Commercial Officer | 57 | 303.91万美元 | 2.10 | 2026-07-24 |
| Laurie A. Miller | 女 | Chief Human Resources Officer and Senior Vice President | 53 | 未披露 | 未持股 | 2026-07-24 |
| Frank W. Chan | 男 | Chief Operating Officer and Executive Vice President | 56 | 333.68万美元 | 0.47 | 2026-07-24 |
董事简历
中英对照 | 中文 | 英文- Claire Pomeroy
-
Claire Pomeroy，2014年以来，她一直担任董事。2013年以来，她一直担任the Albert and Mary Lasker Foundation（私人基金会，通过识别研究人才、公众教育和宣传加快对医学研究的支持来改善健康）的总裁。之前，她担任院长加州大学戴维斯分校（University of California, Davis，UC Davis）医学院院长和加州大学戴维斯分校卫生系统（ UC Davis Health System）首席执行官。她是Expanesthetics, Inc.和the Sierra Health Foundation。的董事会成员。她是Morehouse School of Medicine的信托董事会和the Foundation for Biomedical Research董事成员。
Claire Pomeroy has served since 2013 as President of the Albert and Mary Lasker Foundation, a private foundation that seeks to improve health by accelerating support for medical research through recognition of research excellence, public education and advocacy. Prior thereto, she served as Dean and Vice Chancellor of the University of California, Davis School of Medicine. She is an elected member of the National Academy of Medicine. Dr. Pomeroy is a member of the Board of Directors of Haemonetics Corporation (NYSE: HAE). Dr. Pomeroy also serves on the Board of Directors of the Sierra Health Foundation, Center for Women in Academic Medicine and Science, Science Communication Lab, Science Philanthropy Alliance, Research!America, Geisinger School of Medicine, and Morehoe School of Medicine. - Claire Pomeroy，2014年以来，她一直担任董事。2013年以来，她一直担任the Albert and Mary Lasker Foundation（私人基金会，通过识别研究人才、公众教育和宣传加快对医学研究的支持来改善健康）的总裁。之前，她担任院长加州大学戴维斯分校（University of California, Davis，UC Davis）医学院院长和加州大学戴维斯分校卫生系统（ UC Davis Health System）首席执行官。她是Expanesthetics, Inc.和the Sierra Health Foundation。的董事会成员。她是Morehouse School of Medicine的信托董事会和the Foundation for Biomedical Research董事成员。
- Claire Pomeroy has served since 2013 as President of the Albert and Mary Lasker Foundation, a private foundation that seeks to improve health by accelerating support for medical research through recognition of research excellence, public education and advocacy. Prior thereto, she served as Dean and Vice Chancellor of the University of California, Davis School of Medicine. She is an elected member of the National Academy of Medicine. Dr. Pomeroy is a member of the Board of Directors of Haemonetics Corporation (NYSE: HAE). Dr. Pomeroy also serves on the Board of Directors of the Sierra Health Foundation, Center for Women in Academic Medicine and Science, Science Communication Lab, Science Philanthropy Alliance, Research!America, Geisinger School of Medicine, and Morehoe School of Medicine.
- Christopher Simon
-
Christopher Simon，担任总裁兼首席执行官，于2016年5月加入Haemonetics公司。他此前曾担任McKinsey & Company的高级合伙人，从事全球医疗产品实践。他曾担任McKinsey & Company的顾问（1993年以来），最近担任McKinsey & Company与Haemonetics的战略回顾的领导合伙人。此前，他曾担任Baxter Healthcare Corporation的商业职务。
Christopher Simon,is President and Chief Executive Officer of Haemonetics Corporation. He joined Haemonetics in May 2016 and Haemonetics Corporation Board in September 2016. Mr. Simon previously served as a Senior Partner of McKinsey & Company where he led the Global Medical Products Practice. Mr. Simon served as a consultant with McKinsey & Company beginning in 1993 and was the lead partner for McKinsey & Company's strategy review with Haemonetics that began in October 2015, where he gained invaluable insights into the Company's business and markets. Prior to his career at McKinsey & Company, Mr. Simon served in commercial roles with Baxter Healthcare Corporation and as a U.S. Army Infantry Officer in Korea with the 1st Ranger Battalion. He also currently serves on the Board of Directors of AdvaMed, a global trade association of companies that develop, produce, manufacture and market medical technologies. Mr. Simon earned a Bachelor of Science in Economics from the Wharton School at the University of Pennsylvania and an M.B.A. from Harvard Business School. - Christopher Simon，担任总裁兼首席执行官，于2016年5月加入Haemonetics公司。他此前曾担任McKinsey & Company的高级合伙人，从事全球医疗产品实践。他曾担任McKinsey & Company的顾问（1993年以来），最近担任McKinsey & Company与Haemonetics的战略回顾的领导合伙人。此前，他曾担任Baxter Healthcare Corporation的商业职务。
- Christopher Simon,is President and Chief Executive Officer of Haemonetics Corporation. He joined Haemonetics in May 2016 and Haemonetics Corporation Board in September 2016. Mr. Simon previously served as a Senior Partner of McKinsey & Company where he led the Global Medical Products Practice. Mr. Simon served as a consultant with McKinsey & Company beginning in 1993 and was the lead partner for McKinsey & Company's strategy review with Haemonetics that began in October 2015, where he gained invaluable insights into the Company's business and markets. Prior to his career at McKinsey & Company, Mr. Simon served in commercial roles with Baxter Healthcare Corporation and as a U.S. Army Infantry Officer in Korea with the 1st Ranger Battalion. He also currently serves on the Board of Directors of AdvaMed, a global trade association of companies that develop, produce, manufacture and market medical technologies. Mr. Simon earned a Bachelor of Science in Economics from the Wharton School at the University of Pennsylvania and an M.B.A. from Harvard Business School.
- Diane M. Bryant
-
Diane M. Bryant，是Intel Corporation（高科技产品和服务）的数据中心集团的执行副总裁兼总经理。她曾领导为数字服务经济开发数据中心平台的世界组织。她担任现任职务，负责云服务和通信服务供应商、企业和政府基础设施的数据中心损益表、战略和产品开发，涉及服务器、存储和网络解决方案。此前，她曾担任Intel公司的公司副总裁兼首席信息官，在那里她曾负责公司范围的信息技术解决方案和服务。
Diane M. Bryant served as Chief Executive Officer of NovaSignal Corp., a medical technology and data company specializing in the assessment and management of brain health, from January 2020 to July 2023. She was Chief Operating Officer of Google Cloud at Alphabet Inc. from December 2017 to July 2018. Prior to Alphabet, she held several executive leadership positions at Intel Corporation, including as Group President and Executive Vice President and General Manager of the Data Center Group that develops server, storage and network platforms for the digital services economy and Corporate Vice President and Chief Information Officer. She also serves on the Chancellor's Board of Advisors at the University of California at Davis.Ms. Bryant serves as a director of Haemonetics Corporation and Jacobs Solutions Inc. She served as a director of United Technologies Corporation from January 2017 until its acquisition by Raytheon Company in April 2020. - Diane M. Bryant，是Intel Corporation（高科技产品和服务）的数据中心集团的执行副总裁兼总经理。她曾领导为数字服务经济开发数据中心平台的世界组织。她担任现任职务，负责云服务和通信服务供应商、企业和政府基础设施的数据中心损益表、战略和产品开发，涉及服务器、存储和网络解决方案。此前，她曾担任Intel公司的公司副总裁兼首席信息官，在那里她曾负责公司范围的信息技术解决方案和服务。
- Diane M. Bryant served as Chief Executive Officer of NovaSignal Corp., a medical technology and data company specializing in the assessment and management of brain health, from January 2020 to July 2023. She was Chief Operating Officer of Google Cloud at Alphabet Inc. from December 2017 to July 2018. Prior to Alphabet, she held several executive leadership positions at Intel Corporation, including as Group President and Executive Vice President and General Manager of the Data Center Group that develops server, storage and network platforms for the digital services economy and Corporate Vice President and Chief Information Officer. She also serves on the Chancellor's Board of Advisors at the University of California at Davis.Ms. Bryant serves as a director of Haemonetics Corporation and Jacobs Solutions Inc. She served as a director of United Technologies Corporation from January 2017 until its acquisition by Raytheon Company in April 2020.
- Lloyd E. Johnson
-
LloydE.Johnson于2004年至2015年担任埃森哲公司（Accenture Corporation）的全球财务和内部审计总经理，埃森哲公司是一家全球管理咨询和专业服务公司，提供战略，咨询，数字技术和运营服务。加入Accenture Corporation之前，他曾担任Delphi Automotive plc（汽车零部件制造商）的执行董事、并购和总审计师（从1999年到2004年）。从1997年到1999年，他曾担任Emerson Electric Corporation（多元化的全球制造公司，服务于工业、商业和消费市场）的公司Vice President、财务和首席审计执行官。职业生涯早期，他曾担任Sara Lee Knit Products公司（Sara Lee Corporation的部门）、Shaw Food Industries公司（私人持有的食品服务供应公司）、Harper，Wiggins&Johnson公司（区域会计师事务所）的高级财务领导职务。Johnson先生在Coopers&Lybrand开始了他的职业生涯，该公司是一家全球会计师事务所，后来成为普华永道会计师事务所的一部分。
Lloyd E. Johnson served as Executive Director, M&A and General Auditor for Delphi Automotive PLC from 1999 to 2004 and held senior financial leadership positions at Emerson Electric Corporation, Sara Lee Corporation and Shaw Food Services. Mr. Johnson is a Certified Public Accountant and holds the National Association of Corporate Directors Directorship Certification designation. Mr. Johnson also serves as Chair of the AARP Board of Directors and as a trtee and vice chair on the Biness Partnership Foundation at the Darla Moore School of Biness at the University of South Carolina. - LloydE.Johnson于2004年至2015年担任埃森哲公司（Accenture Corporation）的全球财务和内部审计总经理，埃森哲公司是一家全球管理咨询和专业服务公司，提供战略，咨询，数字技术和运营服务。加入Accenture Corporation之前，他曾担任Delphi Automotive plc（汽车零部件制造商）的执行董事、并购和总审计师（从1999年到2004年）。从1997年到1999年，他曾担任Emerson Electric Corporation（多元化的全球制造公司，服务于工业、商业和消费市场）的公司Vice President、财务和首席审计执行官。职业生涯早期，他曾担任Sara Lee Knit Products公司（Sara Lee Corporation的部门）、Shaw Food Industries公司（私人持有的食品服务供应公司）、Harper，Wiggins&Johnson公司（区域会计师事务所）的高级财务领导职务。Johnson先生在Coopers&Lybrand开始了他的职业生涯，该公司是一家全球会计师事务所，后来成为普华永道会计师事务所的一部分。
- Lloyd E. Johnson served as Executive Director, M&A and General Auditor for Delphi Automotive PLC from 1999 to 2004 and held senior financial leadership positions at Emerson Electric Corporation, Sara Lee Corporation and Shaw Food Services. Mr. Johnson is a Certified Public Accountant and holds the National Association of Corporate Directors Directorship Certification designation. Mr. Johnson also serves as Chair of the AARP Board of Directors and as a trtee and vice chair on the Biness Partnership Foundation at the Darla Moore School of Biness at the University of South Carolina.
- Robert Abernathy
-
Robert Abernathy，Abernathy先生于2017年10月加入董事会，并担任薪酬委员会成员。Abernathy先生曾于2014年10月至2017年6月退休期间担任医疗技术公司Halyard Health Inc.（从金佰利（Kimberly-Clark）分拆而来）的董事长兼首席执行官。Abernathy先生于1982年加入金佰利公司（Kimberly-Clark），这是一家全球性的个人护理产品公司，并担任了越来越重要的职务，包括金佰利公司全球医疗保健业务总裁、发展中和新兴市场集团总裁、金佰利澳大利亚公司董事总经理以及North Atlantic消费品公司总裁。除了他目前的上市公司董事会服务，Abernathy先生此前曾担任Halyard Health，Inc.和RadioShack Corp.的董事。
Robert Abernathy,joined Haemonetics Corporation Board in October 2017 and is Chair of the Compensation Committee and a member of the Governance and Compliance Committee. Mr. Abernathy served as Chairman of the Board of Directors and Chief Executive Officer of Halyard Health Inc., a publicly-traded medical technology company and spin-off from Kimberly-Clark, from October 2014 until his retirement in June 2017 (he continued as Chairman until September 2017). Mr. Abernathy joined Kimberly-Clark, a global personal care products company, in 1982 and held numerous roles of increasing responsibility, including President of Kimberly-Clark's Global Health Care business, Group President, Developing & Emerging Markets, Managing Director, Kimberly-Clark Australia and President, North Atlantic Consumer Products. - Robert Abernathy，Abernathy先生于2017年10月加入董事会，并担任薪酬委员会成员。Abernathy先生曾于2014年10月至2017年6月退休期间担任医疗技术公司Halyard Health Inc.（从金佰利（Kimberly-Clark）分拆而来）的董事长兼首席执行官。Abernathy先生于1982年加入金佰利公司（Kimberly-Clark），这是一家全球性的个人护理产品公司，并担任了越来越重要的职务，包括金佰利公司全球医疗保健业务总裁、发展中和新兴市场集团总裁、金佰利澳大利亚公司董事总经理以及North Atlantic消费品公司总裁。除了他目前的上市公司董事会服务，Abernathy先生此前曾担任Halyard Health，Inc.和RadioShack Corp.的董事。
- Robert Abernathy,joined Haemonetics Corporation Board in October 2017 and is Chair of the Compensation Committee and a member of the Governance and Compliance Committee. Mr. Abernathy served as Chairman of the Board of Directors and Chief Executive Officer of Halyard Health Inc., a publicly-traded medical technology company and spin-off from Kimberly-Clark, from October 2014 until his retirement in June 2017 (he continued as Chairman until September 2017). Mr. Abernathy joined Kimberly-Clark, a global personal care products company, in 1982 and held numerous roles of increasing responsibility, including President of Kimberly-Clark's Global Health Care business, Group President, Developing & Emerging Markets, Managing Director, Kimberly-Clark Australia and President, North Atlantic Consumer Products.
- Diane M. Bryant
-
Diane M. Bryant于2023年8月加入董事会，是薪酬委员会和技术委员会的成员。布莱恩特女士此前曾担任NovaSignal Corp.的董事长兼首席执行官，该公司是一家专门从事脑健康评估和管理的医疗技术和数据公司，自2020年6月起至2023年7月被收购。她此前曾于2017年12月至2018年7月担任谷歌云（云计算服务）的首席运营官，在加入谷歌云之前，她曾在英特尔公司工作了32年，在那里她担任过许多责任越来越大的领导职位，包括数据中心集团的集团总裁。布莱恩特女士在2015年和2016年被《财富》杂志评为商界50位最具影响力的女性之一。除了担任上市公司董事会服务外，布莱恩特还担任Celestial AI（一家风险投资支持的私营公司）的董事，并担任加州大学戴维斯分校财政大臣顾问委员会主席。她此前还曾担任联合技术公司和Jacobs Solutions Inc.的董事。
Diane M. Bryant joined Board in August 2023 and is a member of both the Compensation Committee and the Technology Committee. Ms. Bryant previously served as Chairman and Chief Executive Officer of NovaSignal Corp., a medical technology and data company specializing in the assessment and management of brain health, from June 2020 until its acquisition in July 2023. She previously served as Chief Operating Officer of Google Cloud (cloud computing services) from December 2017 to July 2018 and, prior to Google Cloud, spent 32 years at Intel Corporation where she held numerous leadership positions of increasing responsibility, including Group President of the Data Center Group. Ms. Bryant was named one of Fortune's 50 Most Powerful Women in Business in 2015 and 2016. In addition to her public company board service, Ms. Bryant serves as a director of Celestial AI (a venture capital backed private company) and as Chair of the Chancellor's Board of Advisors at the University of California, Davis. She also previously served as a director of United Technologies Corporation and Jacobs Solutions Inc. - Diane M. Bryant于2023年8月加入董事会，是薪酬委员会和技术委员会的成员。布莱恩特女士此前曾担任NovaSignal Corp.的董事长兼首席执行官，该公司是一家专门从事脑健康评估和管理的医疗技术和数据公司，自2020年6月起至2023年7月被收购。她此前曾于2017年12月至2018年7月担任谷歌云（云计算服务）的首席运营官，在加入谷歌云之前，她曾在英特尔公司工作了32年，在那里她担任过许多责任越来越大的领导职位，包括数据中心集团的集团总裁。布莱恩特女士在2015年和2016年被《财富》杂志评为商界50位最具影响力的女性之一。除了担任上市公司董事会服务外，布莱恩特还担任Celestial AI（一家风险投资支持的私营公司）的董事，并担任加州大学戴维斯分校财政大臣顾问委员会主席。她此前还曾担任联合技术公司和Jacobs Solutions Inc.的董事。
- Diane M. Bryant joined Board in August 2023 and is a member of both the Compensation Committee and the Technology Committee. Ms. Bryant previously served as Chairman and Chief Executive Officer of NovaSignal Corp., a medical technology and data company specializing in the assessment and management of brain health, from June 2020 until its acquisition in July 2023. She previously served as Chief Operating Officer of Google Cloud (cloud computing services) from December 2017 to July 2018 and, prior to Google Cloud, spent 32 years at Intel Corporation where she held numerous leadership positions of increasing responsibility, including Group President of the Data Center Group. Ms. Bryant was named one of Fortune's 50 Most Powerful Women in Business in 2015 and 2016. In addition to her public company board service, Ms. Bryant serves as a director of Celestial AI (a venture capital backed private company) and as Chair of the Chancellor's Board of Advisors at the University of California, Davis. She also previously served as a director of United Technologies Corporation and Jacobs Solutions Inc.
- Ellen M. Zane
-
Ellen M. Zane，塔夫茨医学中心名誉首席执行官，塔夫茨医学创始主席。赞恩女士此前曾在2004年至2011年担任塔夫茨医疗中心总裁兼首席执行官，当时她从该职位退休。在此之前，Zane女士曾担任Mass General Brigham（前身为Partners Healthcare System）的网络总裁，这是一个由哈佛附属麻省总医院和Brigham and Women''s Hospital赞助的医生/医院网络。赞恩女士此前还曾担任马萨诸塞州昆西市昆西医院的首席执行官。Zane女士目前担任Savista的董事，Savista是一家总部位于格鲁吉亚的私营公司，涉及医疗保健收入周期管理；Fiduciary Trust Company，一家私营财富管理公司；以及AgNovos Healthcare，LLC，一家私营医疗设备公司，专注于骨骼健康。Zane女士现任Haemonetics Corporation和Synchrony Financial的董事，此前曾担任Azenta, Inc.、Century Capital Management、Parexel International Corporation、Lincare Holdings Inc.和Press Ganey控股的董事。赞恩女士获得了库里学院、斯通希尔学院、本特利大学和马萨诸塞大学达特茅斯分校的荣誉学位。赞恩女士在美国天主教大学获得听力学和言语语言病理学硕士学位，在乔治华盛顿大学获得学士学位。
Ellen M. Zane currently serves as CEO Emeritus at Tufts Medical Center, and previously served as its President and CEO (2004 to 2011). Ms. Zane served as Network President for Mass General Brigham (formerly Partners Healthcare System), a physician/hospital network sponsored by the Harvard affiliated Massachusetts General Hospital and Brigham and Women's Hospital (1994 to 2004). Prior to joining Mass General Brigham, Ms. Zane served as the CEO of Quincy Hospital.Ms. Zane has also served as a member of the board of directors of the Bank since May 2022. Ms. Zane serves on two other public company boards: Boston Scientific Corporation, a manufacturer of medical devices; and Haemonetics Corporation, a global medical device company and provider of blood and plasma supplies and services. She previously served on the board of directors of Azenta Life Sciences (formerly Brooks Automation), a publicly traded provider of biostorage and life sciences solutions. Ms. Zane received a Bachelor of Arts from George Washington University and a Master of Arts from Catholic University of America. She holds the following honorary degrees: Doctorate of Humane Letters from University of Massachusetts—Dartmouth; Doctorate of Commercial Science from Bentley University; Doctorate of Business Administration from Stonehill College; and Doctorate of Humane Letters from Curry College. - Ellen M. Zane，塔夫茨医学中心名誉首席执行官，塔夫茨医学创始主席。赞恩女士此前曾在2004年至2011年担任塔夫茨医疗中心总裁兼首席执行官，当时她从该职位退休。在此之前，Zane女士曾担任Mass General Brigham（前身为Partners Healthcare System）的网络总裁，这是一个由哈佛附属麻省总医院和Brigham and Women''s Hospital赞助的医生/医院网络。赞恩女士此前还曾担任马萨诸塞州昆西市昆西医院的首席执行官。Zane女士目前担任Savista的董事，Savista是一家总部位于格鲁吉亚的私营公司，涉及医疗保健收入周期管理；Fiduciary Trust Company，一家私营财富管理公司；以及AgNovos Healthcare，LLC，一家私营医疗设备公司，专注于骨骼健康。Zane女士现任Haemonetics Corporation和Synchrony Financial的董事，此前曾担任Azenta, Inc.、Century Capital Management、Parexel International Corporation、Lincare Holdings Inc.和Press Ganey控股的董事。赞恩女士获得了库里学院、斯通希尔学院、本特利大学和马萨诸塞大学达特茅斯分校的荣誉学位。赞恩女士在美国天主教大学获得听力学和言语语言病理学硕士学位，在乔治华盛顿大学获得学士学位。
- Ellen M. Zane currently serves as CEO Emeritus at Tufts Medical Center, and previously served as its President and CEO (2004 to 2011). Ms. Zane served as Network President for Mass General Brigham (formerly Partners Healthcare System), a physician/hospital network sponsored by the Harvard affiliated Massachusetts General Hospital and Brigham and Women's Hospital (1994 to 2004). Prior to joining Mass General Brigham, Ms. Zane served as the CEO of Quincy Hospital.Ms. Zane has also served as a member of the board of directors of the Bank since May 2022. Ms. Zane serves on two other public company boards: Boston Scientific Corporation, a manufacturer of medical devices; and Haemonetics Corporation, a global medical device company and provider of blood and plasma supplies and services. She previously served on the board of directors of Azenta Life Sciences (formerly Brooks Automation), a publicly traded provider of biostorage and life sciences solutions. Ms. Zane received a Bachelor of Arts from George Washington University and a Master of Arts from Catholic University of America. She holds the following honorary degrees: Doctorate of Humane Letters from University of Massachusetts—Dartmouth; Doctorate of Commercial Science from Bentley University; Doctorate of Business Administration from Stonehill College; and Doctorate of Humane Letters from Curry College.
- Mark W. Kroll
-
Mark W. Kroll，2003年起担任本公司董事。他于2005年从St. Jude Medical退休；1995年以来，他在该公司担任过多个行政职务，最近的是心律管理部门的高级副总裁、首席技术官。他在University of Minnesota获得数学学士学位、电气工程硕士和博士学位，在St. Thomas获得工商管理硕士学位。他拥有340多项已批准的美国专利，是以下机构的资深会员：American College of Cardiology、Heart Rhythm Society、Institute of Electronics and Electrical Engineering，和American Institute for Medicine and Biology in Engineering。他也是Haemonetics Corporation的董事。
Mark W. Kroll,retired in July 2005 from St. Jude Medical, Inc., where he held various executive level positions since 1995, most recently as Senior Vice President and Chief Technology Officer, Cardiac Rhythm Management Division. Dr. Kroll holds a B.S. in Mathematics and a M.S. and a Ph.D. from the Electrical Engineering department of the University of Minnesota and an M.B.A. from the University of St. Thomas. Dr. Kroll is also the named inventor of over 350 issued U.S. patents and is a Fellow of: American College of Cardiology, Heart Rhythm Society, Institute of Electronics and Electrical Engineering ("IEEE"), and the American Institute for Medicine and Biology in Engineering ("AIMBE"). Dr. Kroll has also served on the board of Haemonetics Corporation, provider of innovative medical technology solutions, since 2006. - Mark W. Kroll，2003年起担任本公司董事。他于2005年从St. Jude Medical退休；1995年以来，他在该公司担任过多个行政职务，最近的是心律管理部门的高级副总裁、首席技术官。他在University of Minnesota获得数学学士学位、电气工程硕士和博士学位，在St. Thomas获得工商管理硕士学位。他拥有340多项已批准的美国专利，是以下机构的资深会员：American College of Cardiology、Heart Rhythm Society、Institute of Electronics and Electrical Engineering，和American Institute for Medicine and Biology in Engineering。他也是Haemonetics Corporation的董事。
- Mark W. Kroll,retired in July 2005 from St. Jude Medical, Inc., where he held various executive level positions since 1995, most recently as Senior Vice President and Chief Technology Officer, Cardiac Rhythm Management Division. Dr. Kroll holds a B.S. in Mathematics and a M.S. and a Ph.D. from the Electrical Engineering department of the University of Minnesota and an M.B.A. from the University of St. Thomas. Dr. Kroll is also the named inventor of over 350 issued U.S. patents and is a Fellow of: American College of Cardiology, Heart Rhythm Society, Institute of Electronics and Electrical Engineering ("IEEE"), and the American Institute for Medicine and Biology in Engineering ("AIMBE"). Dr. Kroll has also served on the board of Haemonetics Corporation, provider of innovative medical technology solutions, since 2006.
- Michael J. Coyle
-
Michael J. Coyle， 2009年12月起，他担任Cardiac and Vascular Group的执行副总裁和集团总裁。在此之前，2001至2007年，他担任Cardiac Rhythm Management在圣裘德分公司的总裁；先前职位包括公司圣裘德Daig Catheter部门总裁和Eli Lilly & Company的多个领导职位。
Michael J. Coyle,joined Haemonetics Corporation Board in April 2020 and is a member of both the Audit Committee and the Technology Committee. Mr. Coyle previously served as the President and Chief Executive Officer of iRhythm Technologies, Inc., a digital healthcare company, from January 2021 to June 2021. From December 2009 to January 2021, Mr. Coyle served as Executive Vice President and Group President, Cardiac and Vascular Group of Medtronic plc (and its predecessor, Medtronic, Inc.), a global medical device company, where he oversaw four of the company's business divisions. Mr. Coyle previously served as President of the Cardiac Rhythm Management division at St. Jude Medical Inc. from 2001 to 2007 and earlier in his career held numerous leadership positions at St. Jude and Eli Lilly & Company. Mr. Coyle previously served on the boards of iRhythm Technologies, Inc. and of two NASDAQ-listed medical device companies responsible for making catheter-based products. He holds six U.S. patents related to cardiovascular medical device products and technologies. - Michael J. Coyle， 2009年12月起，他担任Cardiac and Vascular Group的执行副总裁和集团总裁。在此之前，2001至2007年，他担任Cardiac Rhythm Management在圣裘德分公司的总裁；先前职位包括公司圣裘德Daig Catheter部门总裁和Eli Lilly & Company的多个领导职位。
- Michael J. Coyle,joined Haemonetics Corporation Board in April 2020 and is a member of both the Audit Committee and the Technology Committee. Mr. Coyle previously served as the President and Chief Executive Officer of iRhythm Technologies, Inc., a digital healthcare company, from January 2021 to June 2021. From December 2009 to January 2021, Mr. Coyle served as Executive Vice President and Group President, Cardiac and Vascular Group of Medtronic plc (and its predecessor, Medtronic, Inc.), a global medical device company, where he oversaw four of the company's business divisions. Mr. Coyle previously served as President of the Cardiac Rhythm Management division at St. Jude Medical Inc. from 2001 to 2007 and earlier in his career held numerous leadership positions at St. Jude and Eli Lilly & Company. Mr. Coyle previously served on the boards of iRhythm Technologies, Inc. and of two NASDAQ-listed medical device companies responsible for making catheter-based products. He holds six U.S. patents related to cardiovascular medical device products and technologies.
高管简历
中英对照 | 中文 | 英文- James C. D'Arecca
James C. D'Arecca自2013年8月起担任此职位。在加入Allergan之前，他在Bausch + Lomb担任过类似的职位。 在加入Bausch + Lomb之前，D'Arecca先生曾在Merck＆Co.和先灵葆雅工作。 他还在普华永道会计师事务所担任了13年的注册会计师。 D'Arecca先生获得了哥伦比亚大学的MBA学位和他的学士学位。 在罗格斯大学会计学。
James C. D'Arecca was appointed Chief Accounting Officer - Global, on August 7 2013. Prior to joining Actavis, Mr. D'Arecca held a similar position at Bausch & Lomb. Prior to joining Bausch & Lomb, Mr. D'Arecca worked for Merck & Co., Inc. where he was Executive Director and Business Development Controller responsible for being the primary liaison between the Controller's organization and the business development and corporate licensing functions. Prior to joining Merck, Mr. D'Arecca was Executive Director and Assistant Controller at Schering-Plough. Mr. D'Arecca also spent 13 years with PricewaterhouseCoopers as a Certified Public Accountant. Mr. D'Arecca received his MBA from Columbia University and his BS in Accounting from Rutgers University.- James C. D'Arecca自2013年8月起担任此职位。在加入Allergan之前，他在Bausch + Lomb担任过类似的职位。 在加入Bausch + Lomb之前，D'Arecca先生曾在Merck＆Co.和先灵葆雅工作。 他还在普华永道会计师事务所担任了13年的注册会计师。 D'Arecca先生获得了哥伦比亚大学的MBA学位和他的学士学位。 在罗格斯大学会计学。
- James C. D'Arecca was appointed Chief Accounting Officer - Global, on August 7 2013. Prior to joining Actavis, Mr. D'Arecca held a similar position at Bausch & Lomb. Prior to joining Bausch & Lomb, Mr. D'Arecca worked for Merck & Co., Inc. where he was Executive Director and Business Development Controller responsible for being the primary liaison between the Controller's organization and the business development and corporate licensing functions. Prior to joining Merck, Mr. D'Arecca was Executive Director and Assistant Controller at Schering-Plough. Mr. D'Arecca also spent 13 years with PricewaterhouseCoopers as a Certified Public Accountant. Mr. D'Arecca received his MBA from Columbia University and his BS in Accounting from Rutgers University.
- Christopher Simon
Christopher Simon，担任总裁兼首席执行官，于2016年5月加入Haemonetics公司。他此前曾担任McKinsey & Company的高级合伙人，从事全球医疗产品实践。他曾担任McKinsey & Company的顾问（1993年以来），最近担任McKinsey & Company与Haemonetics的战略回顾的领导合伙人。此前，他曾担任Baxter Healthcare Corporation的商业职务。
Christopher Simon,is President and Chief Executive Officer of Haemonetics Corporation. He joined Haemonetics in May 2016 and Haemonetics Corporation Board in September 2016. Mr. Simon previously served as a Senior Partner of McKinsey & Company where he led the Global Medical Products Practice. Mr. Simon served as a consultant with McKinsey & Company beginning in 1993 and was the lead partner for McKinsey & Company's strategy review with Haemonetics that began in October 2015, where he gained invaluable insights into the Company's business and markets. Prior to his career at McKinsey & Company, Mr. Simon served in commercial roles with Baxter Healthcare Corporation and as a U.S. Army Infantry Officer in Korea with the 1st Ranger Battalion. He also currently serves on the Board of Directors of AdvaMed, a global trade association of companies that develop, produce, manufacture and market medical technologies. Mr. Simon earned a Bachelor of Science in Economics from the Wharton School at the University of Pennsylvania and an M.B.A. from Harvard Business School.- Christopher Simon，担任总裁兼首席执行官，于2016年5月加入Haemonetics公司。他此前曾担任McKinsey & Company的高级合伙人，从事全球医疗产品实践。他曾担任McKinsey & Company的顾问（1993年以来），最近担任McKinsey & Company与Haemonetics的战略回顾的领导合伙人。此前，他曾担任Baxter Healthcare Corporation的商业职务。
- Christopher Simon,is President and Chief Executive Officer of Haemonetics Corporation. He joined Haemonetics in May 2016 and Haemonetics Corporation Board in September 2016. Mr. Simon previously served as a Senior Partner of McKinsey & Company where he led the Global Medical Products Practice. Mr. Simon served as a consultant with McKinsey & Company beginning in 1993 and was the lead partner for McKinsey & Company's strategy review with Haemonetics that began in October 2015, where he gained invaluable insights into the Company's business and markets. Prior to his career at McKinsey & Company, Mr. Simon served in commercial roles with Baxter Healthcare Corporation and as a U.S. Army Infantry Officer in Korea with the 1st Ranger Battalion. He also currently serves on the Board of Directors of AdvaMed, a global trade association of companies that develop, produce, manufacture and market medical technologies. Mr. Simon earned a Bachelor of Science in Economics from the Wharton School at the University of Pennsylvania and an M.B.A. from Harvard Business School.
- Michelle Basil
Michelle Basil，于2017年3月加入公司，担任执行Vice President，总法律顾问。Basil女士曾于1997年9月至2017年3月担任波士顿律师事务所Nutter，McClennen&Fish LLP的生命科学实践组合伙人兼主席。Basil女士的实践专注于公司法和证券法，包括并购，战略合作伙伴关系和公司治理事务，并代表上市和私营公司，主要是在生命科学和医疗技术行业。Basil女士是马萨诸塞州医疗器械工业委员会（MassMedic）的董事会成员。她获得马萨诸塞州的律师资格，持有加州大学伯克利分校（the University of California at Berkeley）的文学学士学位和法学博士学位。
Michelle Basil,joined the Company in March 2017 as Executive Vice President, General Counsel. Ms. Basil was previously a Partner and Chair of the Life Sciences Practice Group at Nutter, McClennen & Fish LLP, a Boston-based law firm, where she practiced from September 1997 to March 2017. Ms. Basil focused her practice on corporate and securities law, including mergers and acquisitions, strategic partnerships and corporate governance matters, and represented both public and private companies, principally in the life sciences and medical technology industries. Ms. Basil is a member of the Board of Directors of the Massachusetts Medical Device Industry Council (MassMEDIC). She is admitted to the bar in Massachusetts and holds both a Bachelor of Arts and a Juris Doctor from the University of California at Berkeley.- Michelle Basil，于2017年3月加入公司，担任执行Vice President，总法律顾问。Basil女士曾于1997年9月至2017年3月担任波士顿律师事务所Nutter，McClennen&Fish LLP的生命科学实践组合伙人兼主席。Basil女士的实践专注于公司法和证券法，包括并购，战略合作伙伴关系和公司治理事务，并代表上市和私营公司，主要是在生命科学和医疗技术行业。Basil女士是马萨诸塞州医疗器械工业委员会（MassMedic）的董事会成员。她获得马萨诸塞州的律师资格，持有加州大学伯克利分校（the University of California at Berkeley）的文学学士学位和法学博士学位。
- Michelle Basil,joined the Company in March 2017 as Executive Vice President, General Counsel. Ms. Basil was previously a Partner and Chair of the Life Sciences Practice Group at Nutter, McClennen & Fish LLP, a Boston-based law firm, where she practiced from September 1997 to March 2017. Ms. Basil focused her practice on corporate and securities law, including mergers and acquisitions, strategic partnerships and corporate governance matters, and represented both public and private companies, principally in the life sciences and medical technology industries. Ms. Basil is a member of the Board of Directors of the Massachusetts Medical Device Industry Council (MassMEDIC). She is admitted to the bar in Massachusetts and holds both a Bachelor of Arts and a Juris Doctor from the University of California at Berkeley.
- Roy Galvin
Roy Galvin，2022年10月加入Haemonetics，担任全球血浆和血液中心总裁。他负责Haemonetics公司的血浆和血液中心业务，通过收集和捐赠管理解决方案提升公司的领导地位和创新。高尔文先生在全球医疗保健技术领域的丰富经验包括在美敦力公司工作超过25年，他担任的领导职务包括美国颅骨和脊柱技术业务高级副总裁，以及修复治疗集团美洲业务高级副总裁、美国外科技术销售副总裁和神经技术全球营销总监。在职业生涯早期，高尔文先生在Xomed Surgical Products Inc.（在被美敦力收购之前）、Corin Orthopedics、Biomet Corporation，Inc.和Zimmer Orthopedic Inc.担任越来越重要的职务。高尔文先生毕业于朴茨茅斯理工学院。
Roy Galvin,joined Haemonetics in October 2022 as President, Global Plasma and Blood Center. He is responsible for Haemonetics' Plasma and Blood Center businesses, advancing the Company's leadership positions and innovation through its collection and donor management solutions. Mr. Galvin's significant experience in global healthcare technology includes more than 25 years at Medtronic plc, where his leadership roles included Senior Vice President Commercial – US Cranial & Spinal Technologies, as well as positions as Senior Vice President Commercial Americas – Restorative Therapy Group, Vice President US Sales – Surgical Technologies, and Director of Global Marketing – Neurologic Technologies. Earlier in his career, Mr. Galvin held positions of increasing responsibility at Xomed Surgical Products Inc. (prior to its acquisition by Medtronic), Corin Orthopedics, Biomet Corporation, Inc. and Zimmer Orthopedic Inc. Mr. Galvin is a graduate of Portsmouth Polytechnic.- Roy Galvin，2022年10月加入Haemonetics，担任全球血浆和血液中心总裁。他负责Haemonetics公司的血浆和血液中心业务，通过收集和捐赠管理解决方案提升公司的领导地位和创新。高尔文先生在全球医疗保健技术领域的丰富经验包括在美敦力公司工作超过25年，他担任的领导职务包括美国颅骨和脊柱技术业务高级副总裁，以及修复治疗集团美洲业务高级副总裁、美国外科技术销售副总裁和神经技术全球营销总监。在职业生涯早期，高尔文先生在Xomed Surgical Products Inc.（在被美敦力收购之前）、Corin Orthopedics、Biomet Corporation，Inc.和Zimmer Orthopedic Inc.担任越来越重要的职务。高尔文先生毕业于朴茨茅斯理工学院。
- Roy Galvin,joined Haemonetics in October 2022 as President, Global Plasma and Blood Center. He is responsible for Haemonetics' Plasma and Blood Center businesses, advancing the Company's leadership positions and innovation through its collection and donor management solutions. Mr. Galvin's significant experience in global healthcare technology includes more than 25 years at Medtronic plc, where his leadership roles included Senior Vice President Commercial – US Cranial & Spinal Technologies, as well as positions as Senior Vice President Commercial Americas – Restorative Therapy Group, Vice President US Sales – Surgical Technologies, and Director of Global Marketing – Neurologic Technologies. Earlier in his career, Mr. Galvin held positions of increasing responsibility at Xomed Surgical Products Inc. (prior to its acquisition by Medtronic), Corin Orthopedics, Biomet Corporation, Inc. and Zimmer Orthopedic Inc. Mr. Galvin is a graduate of Portsmouth Polytechnic.
- Laurie A. Miller
Laurie A. Miller于2021年8月晋升为Haemonetics高级副总裁兼首席人力资源官。米勒女士于2016年加入Haemonetics，之前担任人力资源副总裁兼人力资源和人才管理高级总监，帮助公司建立以绩效为导向的协作文化，指导以员工为中心的关键举措，并为员工创造一个强大的工作环境。在加入Haemonetics公司之前，米勒女士在企业信息管理公司铁山公司担任越来越重要的职务，包括在2010年2月至2016年4月担任人力资源总监。在职业生涯的早期，米勒女士曾在全球快餐店特许经营商唐恩都乐和建筑管理公司Shawmut Design and Construction担任多个人力资源职位，职责广泛且日益增加。米勒女士在韦斯特菲尔德州立学院获得了商业管理学士学位，在伊曼纽尔学院获得了管理学硕士学位。
Laurie A. Miller,was promoted to Senior Vice President, Chief Human Resources Officer of Haemonetics in August 2021. Ms. Miller joined Haemonetics in 2016 and previously held positions as Vice President, Human Resources and Senior Director, Human Resources and Talent Management, where she helped build the Company's collaborative, performance-driven culture, direct key employee-focused initiatives and create a strong workplace environment for employees. Prior to joining Haemonetics, Ms. Miller served in positions of increasing responsibility at Iron Mountain Inc., an enterprise information management company, including as Director of Human Resources, from February 2010 to April 2016. Earlier in her career, Ms. Miller held various Human Resources positions of broad and increasing responsibility at Dunkin' Brands Group Inc., a global franchisor of quick service restaurants, and Shawmut Design and Construction, a construction management firm. Ms. Miller earned a Bachelor of Science in Business Management from Westfield State College and a Master of Science in Management from Emmanuel College.- Laurie A. Miller于2021年8月晋升为Haemonetics高级副总裁兼首席人力资源官。米勒女士于2016年加入Haemonetics，之前担任人力资源副总裁兼人力资源和人才管理高级总监，帮助公司建立以绩效为导向的协作文化，指导以员工为中心的关键举措，并为员工创造一个强大的工作环境。在加入Haemonetics公司之前，米勒女士在企业信息管理公司铁山公司担任越来越重要的职务，包括在2010年2月至2016年4月担任人力资源总监。在职业生涯的早期，米勒女士曾在全球快餐店特许经营商唐恩都乐和建筑管理公司Shawmut Design and Construction担任多个人力资源职位，职责广泛且日益增加。米勒女士在韦斯特菲尔德州立学院获得了商业管理学士学位，在伊曼纽尔学院获得了管理学硕士学位。
- Laurie A. Miller,was promoted to Senior Vice President, Chief Human Resources Officer of Haemonetics in August 2021. Ms. Miller joined Haemonetics in 2016 and previously held positions as Vice President, Human Resources and Senior Director, Human Resources and Talent Management, where she helped build the Company's collaborative, performance-driven culture, direct key employee-focused initiatives and create a strong workplace environment for employees. Prior to joining Haemonetics, Ms. Miller served in positions of increasing responsibility at Iron Mountain Inc., an enterprise information management company, including as Director of Human Resources, from February 2010 to April 2016. Earlier in her career, Ms. Miller held various Human Resources positions of broad and increasing responsibility at Dunkin' Brands Group Inc., a global franchisor of quick service restaurants, and Shawmut Design and Construction, a construction management firm. Ms. Miller earned a Bachelor of Science in Business Management from Westfield State College and a Master of Science in Management from Emmanuel College.
- Frank W. Chan
Frank W. Chan于2025年4月加入公司，担任执行副总裁、首席运营官。担任这一职务时，陈先生负责监督公司的全球运营、供应链、物流、研发、监管事务和质量保证职能。Chan先生从美敦力 PLC加入公司，2015年至2025年4月，他在多个业务领域担任商业、运营和技术领导职务，最近担任急性护理和监测业务总裁。在担任这一职务期间，他领导了气道管理、患者监测和互联护理解决方案的全球投资组合，推动了增长和产品创新。在加入美敦力之前，Chan先生于2011年至2015年在Covidien plc担任过多个领导职务，在各个职能领域发挥关键作用，包括研发和医疗事务。在其职业生涯的早期，陈先生还曾在美敦力和Depuy Orthopaedics，Inc.担任研发和项目管理职务，承担越来越大的责任。陈先生在私营医疗器械公司Blink Device Company、麻醉患者安全基金会和AdvaMed AAA Technology（AdvaMed全球医疗器械行业协会的一个部门）的董事会任职，该协会代表数字医疗技术公司，并促进数据和数字医疗技术在改变医疗保健方面的关键作用。Chan先生在康考迪亚大学获得机械工程学学士学位，并在麦吉尔大学获得生物医学工程工程学硕士和哲学博士学位。
Frank W. Chan joined the Company in April 2025 as Executive Vice President, Chief Operating Officer. In this role, Mr. Chan oversees the Company's global operations, supply chain, logistics, research and development, regulatory affairs and quality assurance functions. Mr. Chan joined the Company from Medtronic plc, where from 2015 to April 2025 he held commercial, operational and technical leadership positions across multiple businesses, most recently serving as President of the Acute Care & Monitoring business. In this role, he led a global portfolio of airway management, patient monitoring and connected care solutions, driving growth and product innovation. Prior to joining Medtronic, Mr. Chan held various leadership positions at Covidien plc from 2011 to 2015, where he played key roles across functions, including research and development and medical affairs. Earlier in his career, Mr. Chan also held research and development and program management roles of increasing responsibility with Medtronic and DePuy Orthopaedics, Inc. Mr. Chan serves on the boards of Blink Device Company, a privately held medical device company, the Anesthesia Patient Safety Foundation and AdvaMed Digital Health Technology, a division of the AdvaMed global medical device trade association that represents digital medical technology companies and promotes the critical role of data and digital medtech in transforming health care. Mr. Chan earned a Bachelor of Engineering in mechanical engineering from Concordia University and both a Master of Engineering and Doctor of Philosophy in biomedical engineering from McGill University.- Frank W. Chan于2025年4月加入公司，担任执行副总裁、首席运营官。担任这一职务时，陈先生负责监督公司的全球运营、供应链、物流、研发、监管事务和质量保证职能。Chan先生从美敦力 PLC加入公司，2015年至2025年4月，他在多个业务领域担任商业、运营和技术领导职务，最近担任急性护理和监测业务总裁。在担任这一职务期间，他领导了气道管理、患者监测和互联护理解决方案的全球投资组合，推动了增长和产品创新。在加入美敦力之前，Chan先生于2011年至2015年在Covidien plc担任过多个领导职务，在各个职能领域发挥关键作用，包括研发和医疗事务。在其职业生涯的早期，陈先生还曾在美敦力和Depuy Orthopaedics，Inc.担任研发和项目管理职务，承担越来越大的责任。陈先生在私营医疗器械公司Blink Device Company、麻醉患者安全基金会和AdvaMed AAA Technology（AdvaMed全球医疗器械行业协会的一个部门）的董事会任职，该协会代表数字医疗技术公司，并促进数据和数字医疗技术在改变医疗保健方面的关键作用。Chan先生在康考迪亚大学获得机械工程学学士学位，并在麦吉尔大学获得生物医学工程工程学硕士和哲学博士学位。
- Frank W. Chan joined the Company in April 2025 as Executive Vice President, Chief Operating Officer. In this role, Mr. Chan oversees the Company's global operations, supply chain, logistics, research and development, regulatory affairs and quality assurance functions. Mr. Chan joined the Company from Medtronic plc, where from 2015 to April 2025 he held commercial, operational and technical leadership positions across multiple businesses, most recently serving as President of the Acute Care & Monitoring business. In this role, he led a global portfolio of airway management, patient monitoring and connected care solutions, driving growth and product innovation. Prior to joining Medtronic, Mr. Chan held various leadership positions at Covidien plc from 2011 to 2015, where he played key roles across functions, including research and development and medical affairs. Earlier in his career, Mr. Chan also held research and development and program management roles of increasing responsibility with Medtronic and DePuy Orthopaedics, Inc. Mr. Chan serves on the boards of Blink Device Company, a privately held medical device company, the Anesthesia Patient Safety Foundation and AdvaMed Digital Health Technology, a division of the AdvaMed global medical device trade association that represents digital medical technology companies and promotes the critical role of data and digital medtech in transforming health care. Mr. Chan earned a Bachelor of Engineering in mechanical engineering from Concordia University and both a Master of Engineering and Doctor of Philosophy in biomedical engineering from McGill University.